Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is characterized by aggressive growth and a high propensity for recurrence and metastasis. Simultaneous overexpression of c-MET and EGFR in TNBC is associated with worse clinicopathological features and unfavorable outcomes. Although the development of new c-MET inhibitors and the emergence of 3^rd-generation EGFR inhibitors represent promising treatment options, the high costs involved limit the accessibility of these drugs. In the present study, we sought to investigate the therapeutic potential of doxazosin (DOXA), a generic drug for benign prostate hyperplasia, in targeting TNBC.

Methods

The effect of DOXA on TNBC cell lines in vitro was evaluated in terms of cell viability, apoptosis, c-MET/EGFR signaling pathway

SUBMITTER: Kim S 

PROVIDER: S-EPMC10625208 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature